木瓜直播

Cancer patients with blood types A, B, and AB appear to have a greater risk of as compared with patients who have type O. (Blood Advances)

Male sex hormones' interaction with T cells may explain why to cancer immunotherapy for tumors unrelated to reproductive organs. (Ohio State University, Science Immunology)

In a study involving preclinical models, showed promise for targeting and treating solid tumors. (Mayo Clinic, Science Translational Medicine)

TG Therapeutics announced of its biologics license application/supplemental new drug application for the U2 combination (ublituximab plus umbralisib [Ukoniq]) for chronic lymphocytic leukemia and small lymphocytic lymphoma after an updated analysis of a randomized trial showed a continual survival imbalance.

Nektar Therapeutics and Bristol Myers Squibb jointly announced involving bempegaldesleukin and nivolumab (Opdivo) after planned interim analyses of two late-stage clinical trials in renal cell carcinoma and bladder cancer showed no significant improvement in outcomes versus control arms.

Genmab and AbbVie announced that a phase I/II trial of the bispecific antibody epcoritamab for relapsed/refractory large B-cell lymphoma exceeded the , showing an overall response rate of 63.1%.

The FDA has lifted a on studies of the investigational drug magrolimab plus azacitidine in acute myelogenous leukemia and myelodysplastic syndrome, Gilead Sciences announced.

Curis announced that the FDA has placed a on a phase I/II trial of the IRAK-4 kinase inhibitor emavusertib in patients with lymphoma, following the company's voluntary pause in enrollment for the trial after the FDA previously placed a partial hold on a leukemia trial of the drug.

GlaxoSmithKline agreed to for $1.9 billion -- a 39% premium -- to expand its presence in the oncology market. (Bloomberg)

Restricting might help improve outcomes in diffuse midline glioma, a type of pediatric brain cancer. (University of Pittsburgh, Children's Hospital of Pittsburgh)

Comment